How are cell and gene therapies changing drug development models?

• Life Sciences
• Infographics

What is driving obesity market growth and what does that mean for manufacturers?

Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...

• Life Sciences
• CRA Insights

Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development

Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...

• International Arbitration
• CRA Hosted Event

• November 17, 2026
• New York, NY

China’s Growing Role in Life Sciences: Preparing for the Next Wave of Cross-Border Disputes

As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape. In this...

• Life Sciences
• Speaking Engagement

• November 19, 2026
• Toronto, ON

OBA Business Law Program "Advertising & Marketing Law: What’s New, What’s Next"

Daniel Shack is a panelist during the session titled “Survey Says…” In recent proceedings, consumer survey evidence has been tendered. What’s it for? What’s it...